Summit Therapeutics SMMT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's investing cash flow?
- Summit Therapeutics (SMMT) reported investing cash flow of -$238K in Q1 2026.
- How has Summit Therapeutics's investing cash flow changed year-over-year?
- Summit Therapeutics's investing cash flow decreased by 100.1% year-over-year, from $160.11M to -$238K.
- What does investing cash flow mean?
- The net cash impact of buying or selling assets and investments.
- How do you interpret investing cash flow?
- Negative values typically indicate heavy investment in property, plant, equipment, or securities, while positive values often result from the liquidation of investment portfolios to fund operations.
- How does investing cash flow compare across companies?
- Standard across all industries; biotechs often show negative values due to heavy investment in R&D infrastructure or short-term securities.